LA MESA, Calif., June 1, 2005 (PRIMEZONE) -- Nicodrops, Inc. (Pink Sheets:NCDP), developer of the drug-free, non-nicotine smoking alternative, herbal dietary supplement, LOZENGE(i), today announced the company has received a second order for Nicodrops from Walgreen Co., the nation's largest drugstore chain with $37.5 billion in sales during fiscal 2004. The order has already been shipped to Walgreens and is approximately the same number of units as the initial order. The initial Walgreen order, which was Nicodrops' largest, reaching more than 4,700 Walgreens locations, was announced on April 8, 2005.
"We believe this second order reflects brisk sales as well as confidence from the nation's largest drugstore chain in our product," said Christopher Calpito, president and CEO of Nicodrops, Inc. "Clearly, consumer demand for drug-free, herbal, non-nicotine smoking alternatives is a growing segment. In fact, we believe the market opportunity for Nicodrops will be quite significant. We have high expectations that 2005 will be a big year for market penetration with the Nicodrops brand."(i)
About Walgreen Co.:
Walgreen Co. is the nation's largest drugstore chain with fiscal 2004 sales of $37.5 billion. The company operates 4,738 stores in 45 states and Puerto Rico. Walgreens also provides additional services to pharmacy patients and prescription drug plans through Walgreens Health Initiatives (a pharmacy benefits manager), Walgreens Mail Service, Walgreens Specialty Pharmacy and Walgreens Home Care.
About Nicodrops
Nicodrops Inc., La Mesa, CA, developed a drug free, non-nicotine product which helps reduce the stress associated with not smoking, using all natural herbs.(i) For more information, go to http://www.nicodrops.com or call 1-866-844-5383.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. The words "believe," "expect," "anticipate", and "project", and similar expressions identify forward-looking statements, which speak only as of the date the statement was made. Such statements may include, but not be limited to, projections of revenues, income or loss, expenses, plans, and assumptions relating to the foregoing. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future results could differ materially from those described in forward-looking statements.
(i) These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any diseases.